Cerebras Systems (CBRS) Stock Falls Despite Earnings Beat

Cerebras Systems Inc. designs and sells specialized AI chips, and its first earnings report as a public company sent shares tumbling sharply even though the results beat Wall Street forecasts. The Cerebras Systems stock decline on Wednesday left the NASDAQ:CBRS shares near their lowest point since the IPO.

At a Glance

• CBRS closed at $188.00, down 17.21% on the day
• 52-week range: $185.22 to $386.34; market cap $49.79 billion
• Q1 revenue of $193.4 million beat the analyst consensus by roughly $10 million
• Adjusted gross margin guidance of 36% to 38% for Q2, down from 47% in Q1
• Morgan Stanley raised its price target to $273 from $250 on Wednesday

A Strong Quarter That the Market Punished Anyway

Cerebras reported first quarter revenue of $193.4 million, beating the analyst consensus compiled by Visible Alpha by about $10 million. The adjusted net loss came in at $2.48 million, narrower than analysts had anticipated. By conventional standards, that is a clean beat on both lines for a company reporting its first set of numbers as a public company.

The market's reaction told a different story. Shares opened deep in the red Wednesday morning, touching levels near the stock's all time low since it began trading last month. At $188.00 the stock sits just $2.78 above its IPO price of $185, meaning investors who bought at the offering have barely broken even while those who piled in on the first day of trading are sitting on losses approaching 40%.

The catalyst for the selloff appears to be margin compression. Cerebras guided for adjusted gross margins of 36% to 38% in the current quarter, a meaningful step down from the 47% the company delivered in Q1. For a high-growth chipmaker where investors expect expanding profitability as scale increases, a guided decline of that magnitude raises questions about cost structure and pricing power.

Morgan Stanley Pushes Back on the Selloff

Not everyone is reading the numbers the same way. Morgan Stanley analysts told clients in a note Wednesday that they remain bullish, lifting their price target to $273 from $250. The analysts cited strong demand for Cerebras chips and wrote that nothing in the results was disappointing. They also suggested the company may be taking a conservative posture on guidance as it finds its footing through its first few quarters of public reporting.

That $273 target implies roughly 45% upside from Wednesday's close, which is a substantial call. Whether the market comes around to that view may depend on whether the margin dip is seen as a one quarter blip or the beginning of a structural squeeze.

What the Numbers Say

Valuation at a $49.79 billion market cap on a company still generating adjusted losses is aggressive by any measure. There is no reported price to earnings ratio or earnings per share figure available, because Cerebras is not yet profitable on a GAAP basis. Investors are pricing in a future where the company's custom AI silicon commands durable pricing power, a bet that hinges on competitive positioning against far larger rivals.

Momentum is deteriorating. The RSI reading of 34.04 places the stock just above oversold territory, and the 52-week range of $185.22 to $386.34 illustrates how far CBRS has fallen from its highs. The stock is now trading close to the very bottom of that range. There is no dividend, which is expected for a company at this stage, but it means investors are entirely dependent on price appreciation for any return.

The bull case rests on genuine demand for Cerebras hardware in AI data center buildouts, a Q1 beat that suggests the business is scaling, and analyst confidence as reflected in the Morgan Stanley upgrade. The bear case centers on the margin guidance, the stock's proximity to its IPO price despite billions in market cap, and the reality that the broader AI chip market is fiercely competitive.

Frequently Asked Questions

Why did Cerebras stock fall after a earnings beat?

The company's Q2 gross margin guidance of 36% to 38% came in well below the 47% posted in Q1, raising concerns about cost pressures. Investors appear to have focused on that forward looking warning rather than the better than expected Q1 results.

How does CBRS compare to its IPO price?

At $188.00, the stock is approximately 4% above its IPO price of $185. However, investors who bought on the first trading day are down close to 40% from those levels.

What is Morgan Stanley's price target for CBRS?

Morgan Stanley raised its target to $273 on Wednesday, up from $250, citing strong chip demand and suggesting guidance may reflect conservative management rather than weakening fundamentals.

Is Cerebras profitable?

Not yet on a GAAP basis. The Q1 adjusted net loss was $2.48 million, which was smaller than analysts forecast, but the company remains in investment mode.

Where Things Stand After the Debut Quarter

Cerebras has cleared its first quarterly hurdle as a public company on the revenue line, but the margin outlook has opened a real debate about the stock's near term trajectory. With the RSI near oversold levels and the price hugging the bottom of its annual range, the next few quarters of margin data will carry significant weight with investors.